Promising lymphoma combo trial halted after just 8 patients
NCT ID NCT04541017
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 38 times
Summary
This early-phase trial tested two lab-made antibodies, magrolimab and mogamulizumab, together in people with a type of T-cell lymphoma (mycosis fungoides or Sezary syndrome) that had returned or stopped responding to prior treatments. The goal was to find the best dose and see if the combination could shrink tumors or slow the disease. However, the study was terminated early after enrolling only 8 participants, so we have very little information about how well it worked or what side effects occurred.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016, United States
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
-
NYP/Weill Cornell Medical Center
New York, New York, 10065, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Stanford Cancer Institute Palo Alto
Palo Alto, California, 94304, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792, United States
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Magrolimab and mogamulizumab (monoclonal antibodies)
What this could lead to
If it had succeeded, this combination might have offered a new option for patients with T-cell lymphoma that stopped responding to other treatments.
What could go wrong
The trial was terminated early with only 8 participants, so results are very limited. It is unclear if the combination is safe or effective.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.